<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963741</url>
  </required_header>
  <id_info>
    <org_study_id>LTD4NAPT201218</org_study_id>
    <nct_id>NCT01963741</nct_id>
  </id_info>
  <brief_title>Leukotriene D4 Nasal Provocation Test in Allergic Rhinitis</brief_title>
  <official_title>Leukotriene D4 Nasal Provocation Test: Rationale, Methodology, Diagnostic Value and Its Impact on Airway Inflammation in Allergic Rhinitis With or Without Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leukotrienes play critical roles in the inflammatory process in allergic rhinitis and
      bronchial asthma, therefore, anti-leukotriene therapy is part of treatment for asthma.
      However, not all allergic rhinitis accompanied with or without asthma treated with
      anti-leukotriene were effective. So it is critical to develop a method to identify the
      response subgroup. In this study, it is assumed that nasal physiological responsiveness to
      leukotriene nasal provocation test (NPT) is able to gain evidence on the effect of
      leukotriene on the development of allergic rhinitis and asthma, and is helpful to the use of
      anti-leukotriene agent. The purpose of the study is to establish the methodology and
      diagnostic value of leukotriene D4 (LTD4) nasal provocation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasal provocation test induced by LTD4 will be conducted by measuring nasal airway resistance
      and airway symptoms in a stepwise concentration of LTD4 by nasal spray. Inflammation
      biomarkers, such as eosinophilic granulocyte in sputum and nasal lavage, fractional exhaled
      nitric oxide(FeNO), and lung function before and after nasal provocation will be studied to
      explore the impact of LTD4 nasal provocation test on airway inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants positive response to leukotriene D4 or histamine nasal provocation test</measure>
    <time_frame>Until 1 hour after the nasal provocation test</time_frame>
    <description>Nasal airway resistance measured by positive anterior rhinomanometry. Concentration induced 60% increase of nasal airway resistance (PC60-NAR) will be measured and reported; Composite symptoms score defined by reichmann H and his colleagues showed as follows:3-5 sneezes = 1 point (pt), &gt;5 sneezes = 2 points (pts); rhinorrhoea &lt; 1 milliliter (mL) = 1 pt, rhinorrhoea &gt; 1 milliliter = 2 pts; pruritus of the palate or ear or eye= 1 pt, conjunctivitis or cough or urticaria or difficult breathing= 2 pts. Total score ranges from 0 to 6 pts. Positive response to LTD4 nasal provocation test was defined as PC60-NAR less than 16mcg/mL or the symptom score higher than 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of eosinophils in sputum and nasal lavage and fractional exhaled nitric oxide (FeNO)</measure>
    <time_frame>4 and 24 hours after the nasal provocation test</time_frame>
    <description>Biomarkers in upper and lower airways such as eosinophils in sputum and nasal lavage and fractional exhaled nitric oxide (FeNO) will be studied.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline of cumulative dosage of methacholine causing a 20% fall in forced expiratory volume in 1 second (PD20FEV1-MCH)</measure>
    <time_frame>Half an hour after nasal provocation test</time_frame>
    <description>The increase of brochial hyperresponsiveness induced by nasal provocation test was assessed by the decrease of cumulative dosage of methacholine causing a 20% fall in forced expiratory volume in 1 second (PD20FEV1-MCH).</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak Nasal Inspiratory Flow (PNIF)</measure>
    <time_frame>3 minutes after each concentration of provocation agent administrated into the nostrils</time_frame>
    <description>The peak nasal inspiratory flow (PNIF) is measured by PNIF meter (in-check dial, Clement Clarke International Ltd.); Change from baseline of peak nasal inspiratory flow (PNIF) at the end of nasal provocation test will be reported.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>leukotriene D4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>histamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leukotriene D4</intervention_name>
    <description>Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was &lt;30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.</description>
    <arm_group_label>histamine</arm_group_label>
    <other_name>Cayman chemical company (1-800-364-9897 Cat 20310).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>histamine</intervention_name>
    <description>Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was &lt;30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.</description>
    <arm_group_label>leukotriene D4</arm_group_label>
    <other_name>Guangzhou chemical company (serial number: 1703 )</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with allergic rhinitis accompanied with or without asthma

          -  positive skin prick test (SPT)

          -  had no acute upper or lower airway infection 2 weeks prior to study

          -  no oral or nasal anti-histamines

          -  no leukotriene receptor antagonists for 1 week

          -  no oral or nasal and inhaled corticosteroids for 2 weeks

        Exclusion Criteria:

          -  smokers

          -  a past confirmed history of chronic respiratory disease other than asthma

          -  other severe systemic diseases (myocardial infarction, malignant tumor, etc.)

          -  under immunotherapy

          -  unable to complete the test or had limited understanding

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinping Zheng, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou Institute of Respiratory Disease</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou institute of respiratory disease</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy. 1996 Aug;26(8):868-79. Review.</citation>
    <PMID>9011329</PMID>
  </reference>
  <reference>
    <citation>Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy. 2000;55 Suppl 64:7-16. Review.</citation>
    <PMID>11291780</PMID>
  </reference>
  <reference>
    <citation>Patel P, Philip G, Yang W, Call R, Horak F, LaForce C, Gilles L, Garrett GC, Dass SB, Knorr BA, Reiss TF. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005 Dec;95(6):551-7.</citation>
    <PMID>16400895</PMID>
  </reference>
  <reference>
    <citation>Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, Tozzi CA, Dass SB, Reiss TF. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007 May-Jun;28(3):296-304.</citation>
    <PMID>17619558</PMID>
  </reference>
  <reference>
    <citation>Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy. 2006 Jun;61(6):737-42. Erratum in: Allergy. 2006 Sep;61(9):1153.</citation>
    <PMID>16677244</PMID>
  </reference>
  <reference>
    <citation>Pinar E, Eryigit O, Oncel S, Calli C, Yilmaz O, Yuksel H. Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis. Auris Nasus Larynx. 2008 Mar;35(1):61-6. Epub 2007 Sep 7.</citation>
    <PMID>17826020</PMID>
  </reference>
  <reference>
    <citation>Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887-901. Review.</citation>
    <PMID>17428106</PMID>
  </reference>
  <reference>
    <citation>Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med. 2006 Nov;100(11):1952-9. Epub 2006 Apr 12.</citation>
    <PMID>16626955</PMID>
  </reference>
  <reference>
    <citation>Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy. 1986 Jul;16(4):289-97.</citation>
    <PMID>2427255</PMID>
  </reference>
  <reference>
    <citation>Miadonna A, Tedeschi A, Leggieri E, Lorini M, Folco G, Sala A, Qualizza R, Froldi M, Zanussi C. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis. 1987 Aug;136(2):357-62.</citation>
    <PMID>3039881</PMID>
  </reference>
  <reference>
    <citation>Brozek JL, Baena-Cagnani CE, Bonini S, Canonica GW, Rasi G, van Wijk RG, Zuberbier T, Guyatt G, Bousquet J, Schünemann HJ. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy. 2008 Jan;63(1):38-46. Review.</citation>
    <PMID>18053015</PMID>
  </reference>
  <reference>
    <citation>Riechelmann H, Bachert C, Goldschmidt O, Hauswald B, Klimek L, Schlenter WW, Tasman AJ, Wagenmann M; German Society for Allergology and Clinical Immunology (ENT Section); Working Team for Clinical Immunology. [Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology]. Laryngorhinootologie. 2003 Mar;82(3):183-8. German.</citation>
    <PMID>12673517</PMID>
  </reference>
  <reference>
    <citation>Guan W, Zheng J, Gao Y, Jiang C, Xie Y, An J, Yu X, Liu W, Zhong N. Leukotriene D4 and methacholine bronchial provocation tests for identifying leukotriene-responsiveness subtypes. J Allergy Clin Immunol. 2013 Feb;131(2):332-8.e1-4. doi: 10.1016/j.jaci.2012.08.020. Epub 2012 Oct 4.</citation>
    <PMID>23040886</PMID>
  </reference>
  <reference>
    <citation>Guan W, Zheng J, Gao Y, Jiang C, An J, Yu X, Liu W. Leukotriene D4 bronchial provocation test: methodology and diagnostic value. Curr Med Res Opin. 2012 May;28(5):797-803. doi: 10.1185/03007995.2012.678936. Epub 2012 May 3.</citation>
    <PMID>22435894</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Jinping Zheng</investigator_full_name>
    <investigator_title>Professor,Guangzhou institute of respiratory disease</investigator_title>
  </responsible_party>
  <keyword>Leukotriene D4</keyword>
  <keyword>allergic rhinitis</keyword>
  <keyword>nasal airway resistance</keyword>
  <keyword>nasal provocation test</keyword>
  <keyword>nasal hyperreactivity</keyword>
  <keyword>airway inflammation</keyword>
  <keyword>asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

